Releases
SLNO
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest SOLENO THERAPEUT (SLNO) stock and general news. This information may help you make smarter investment decisions.
About SLNO
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for the treatment of rare diseases. Its lead drug Diazoxide Choline Controlled-Release tablets (DCCR) is a potent ATP-sensitive potassium (KATP) channel activator. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like Prader-Willi syndrome (PWS) to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. It appears that many of the problematic behaviors in conditions like PWS may have hyperphagic drive as a root cause and may therefore be improved by addressing hyperphagia. The Company has a Fast-Track designation for DCCR in PWS and orphan drug designation for the drug in the United States and European Union.